SCHEMBL16764299

SCHEMBL16764299

COC(=O)c1c(N)nc2ccc(C(F)(F)F)nn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.48
MAPK9 P45984 2/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
ABL1 P00519 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
MET P08581 1/20 0.48
PDGFRA P16234 1/20 0.48
PRKACA P17612 1/20 0.48
LTK P29376 1/20 0.48
GRK5 P34947 1/20 0.48
KDR P35968 1/20 0.48
CSNK1A1 P48729 1/20 0.48
CDK8 P49336 1/20 0.48
CLK2 P49760 1/20 0.48
CDK7 P50613 1/20 0.48
CDK9 P50750 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16765148 0.83 AKT1 (0.37) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL18817185 0.81 DAPK3 (0.52) MAPK8MAPK9DAPK3JAK2PRKD3
SCHEMBL18817005 0.80 CDK5 (0.51) MAPK8MAPK9DAPK3JAK2PRKD3
SCHEMBL18366059 0.74 RIPK1 (0.46) CFTRALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL125591 0.70 TUBB4A (0.53) ABL1CFTRALDH1A1KDM4ESMN1; SMN2
SCHEMBL30845864 0.69 PDE10A (0.43) CSF1RRETLTKCSNK1A1CDK8
SCHEMBL26128177 0.68 CFTR (0.49) CFTRALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL18817149 0.68 FYN (0.46) MAPK8MAPK9DAPK3JAK2PRKD3
SCHEMBL24066285 0.68 PDE4A (0.47) MAPK1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL30852200 0.67 NPSR1 (0.42) MAP4K4KDRCFTRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160326180-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-11-10 US disclosed
EP-3077393-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2016-10-12 EP disclosed
US-20150158868-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-06-11 US disclosed
WO-2015084384-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158868-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, MAP3K20, CHEK1 MAPK8 226/4885MAPK9 191/4885DAPK3 279/4885
US-20160326180-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, MAP3K20, CHEK1 MAPK8 226/4885MAPK9 191/4885DAPK3 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.